METASTASIS OF RENAL CANCER TO BREAST: DESCRIPTION OF CLINICAL CASE
E. V. Chernova,
V. A. Khaylenko,
L. G. Zhukova,
A. G. Abdullaev,
D. V. Komov,
L. N. Lyubchenko,
A. V. Khaylenkо,
N. E. Kudashkin,
D. A. Burov https://doi.org/10.17650/1726-9776-2018-14-3-128-132
Abstract
The main method of treatment of local stages of clear cell renal cancer is surgical. The question of conducting adjuvant irradiation and chemotherapy after radical operations is open. Patients with solitary distant metastases and a favorable prognosis may become candidates for surgical treatment. Surgical removal of isolated solitary metastases allows to achieve 35–60 % of 5-year overall survival. The patient, observed in N.N. Blokhin National Medical Research Center of Oncology with metastasis of renal cancer in the pancreas, and then in the breast is an extremely rare clinical case presented in this article.
About the Authors
E. V. Chernova
Department of Oncology the Faculty of Additional Professional Education, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Competing Interests: No conflict of interest.
Russian Federation
1 Ostrovityanova St., Moscow 117997.
Competing Interests: No conflict of interest.
V. A. Khaylenko
Department of Oncology the Faculty of Additional Professional Education, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
1 Ostrovityanova St., Moscow 117997; 23 Kashirskoe Shosse, Moscow 115478.
Competing Interests: No conflict of interest.
Russian Federation
1 Ostrovityanova St., Moscow 117997; 23 Kashirskoe Shosse, Moscow 115478.
Competing Interests: No conflict of interest.
L. G. Zhukova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests: No conflict of interest.
Russian Federation
23 Kashirskoe Shosse, Moscow 115478.
Competing Interests: No conflict of interest.
A. G. Abdullaev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests: No conflict of interest.
Russian Federation
23 Kashirskoe Shosse, Moscow 115478.
Competing Interests: No conflict of interest.
D. V. Komov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests: No conflict of interest.
Russian Federation
23 Kashirskoe Shosse, Moscow 115478.
Competing Interests: No conflict of interest.
L. N. Lyubchenko
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests: No conflict of interest.
Russian Federation
23 Kashirskoe Shosse, Moscow 115478.
Competing Interests: No conflict of interest.
A. V. Khaylenkо
Department of Oncology the Faculty of Additional Professional Education, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
1 Ostrovityanova St., Moscow 117997; 23 Kashirskoe Shosse, Moscow 115478.
Competing Interests: No conflict of interest.
Russian Federation
1 Ostrovityanova St., Moscow 117997; 23 Kashirskoe Shosse, Moscow 115478.
Competing Interests: No conflict of interest.
N. E. Kudashkin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; Department of Oncology and Radiation Therapy the Faculty of Additional Professional Education, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Competing Interests: No conflict of interest.
Russian Federation
23 Kashirskoe Shosse, Moscow 115478; 1 Ostrovityanova St., Moscow 117997.
Competing Interests: No conflict of interest.
D. A. Burov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests: No conflict of interest.
Russian Federation
23 Kashirskoe Shosse, Moscow 115478.
Competing Interests: No conflict of interest.
References
1. Malignant tumors inRussia in 2015 (morbidity and mortality).Eds.: А.D. Kaprin, V.V. Starinskiy,G.V. Petrova. Moscow: MNIOIim. P.A. Gertsena – filial FGBU “NMIRTS”Minzdrava Rossii, 2017. 250 p. (In Russ.).
2. Dimitriadis J., Bamias A. Adjuvant therapyin renal-cell carcinoma: Is it prime timeyet? Translat Cancer Res 2017;6(2):360–2.
3. Wahner-Roedler D.L., Sebo T.J. Renal cellcarcinoma: diagnosis based on metastatic manifestations. Mayo Clin Proc1997;72(10):935–41. PMID: 9379697.
4. Falco G., Buggi F., Sanna P.A. et al. Breast metastases from a Renal Cell Carcinoma. A case report and review of the literature. Int J Surg Case Rep 2014;5(4):193–5. DOI: 10.1016/j.ijscr.2014.01.019. PMID: 24632302.
5. Sindoni A., Rizzo M., Tuccari G. et al. Thyroid metastases from renal cellcarcinoma: review of the literature. Scientific World Journal 2010;10:590–602. DOI: 10.1100/tsw.2010.55.PMID: 20364245.
6. Cheng S.K., Chuah K.L. Metastatic renalcell carcinoma to the pancreas: a review.Arch Pathol Lab Med 2016;140(6):598–602. DOI: 10.5858/arpa.2015-0135-RS. PMID: 27232353.
7. Tatoğlu M.T., Ozülker T., Değirmenci H.,Sayιlgan A.T. Subcutaneous fatty tissuemetastasis from renal cell carcinoma detected with fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging. Indian J Nucl Med 2011;26(1):27–30. DOI: 10.4103/0972-3919.84608. PMID: 21969776.
8. Surov A., Hainz M., Holzhausen H.J. et a l. Skeletal muscle metastases: primarytumours, prevalence, and radiological features. Eur Radiol 2010;20(3):649–58.DOI: 10.1007/s00330-009-1577-1.PMID: 19707767.
9. Rasco D.W., Assikis V., Marshall F. Integrating metastasectomy in the management of advanced urological malignancies – where are we in 2005? J Urol2006;176(5):1921–6. DOI: 10.1016/j.juro.2006.07.003. PMID: 17070212.
10. Sperti C., Moletta L., Patanè G. Metastatic tumors to the pancreas: the role of surgery. World J Gastrointest Oncol2014;6(10):381–92. DOI: 10.4251/wjgo.v6.i10.381. PMID: 25320654.
11. Ravaud A., Motzer R.J., Pandha H.S. et a l. Adjuvant sunitinib in high-risk renalcell carcinoma after nephrectomy. N EnglJ Med 2016;375(23):2246–54.DOI: 10.1056/NEJMoa1611406.PMID: 27718781.
12. Matveev V.B., Roshchin D.A., Peters M.V. Treatment of patients with generalized kidney cancer. Report: Palliative nephrectomy with generalized kidney cancer. Vestnik Moskovskogo onkologicheskogo obshchestva = Bulletin of the Moscow Cancer Society 2010;(3):19. (In Russ.).
13. Alekseev B.Ya., Rusakov I.G., Kalpinskiy A.S. Treatment of patients with generalized kidney cancer. Report: Targeted therapy in the treatment of patients with metastatic kidney cancer. Vestnik Moskovskogo onkologicheskogo obshchestva = Bulletin of the Moscow Cancer Society 2010;(3):17. (In Russ.).
14. Mazza C., Escudier B., Albiges L. Nivolumab in renal cell carcinoma: latest evidence and clinical potential. Ther Adv Med Oncol 2017;9(3):171–81. DOI: 10.1177/1758834016679942. PMID: 28344662.
15. Hirota T., Tomida T., Iwasa M. et al. Solitary pancreatic metastasis occurring eight years after nephrectomy for renal cell carcinoma. A case report and surgical review. Int J Pancreatol 1996;19(2):145– 53. DOI: 10.1007/BF02805229. PMID: 8723558.
Review
For citations:
Chernova E.V., Khaylenko V.A., Zhukova L.G., Abdullaev A.G., Komov D.V., Lyubchenko L.N., Khaylenkо A.V., Kudashkin N.E., Burov D.A. METASTASIS OF RENAL CANCER TO BREAST: DESCRIPTION OF CLINICAL CASE. Cancer Urology. 2018;14(3):128-132. (In Russ.) https://doi.org/10.17650/1726-9776-2018-14-3-128-132
Views:
791
Email this article 